Substance P Follow-up to a Pilot Study of Aprepitant vs Placebo Combined With Standard Antiemetics for the Control of Nausea and Vomiting During Hematopoietic Cell Transplantation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- OHSU Knight Cancer Institute
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Average, median, and mode for substance P levels at different times
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant.
Detailed Description
OBJECTIVES: Primary * To compare the amount of substance P in serum samples from patients with cancer treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation. Secondary * To assess the changes in substance P over time to see if there is an optimal time shown by this physiologic correlate to discontinue substance P blockade after the chemotherapy regimen is completed in these patients. OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes in substance P levels. Patients' medical records are reviewed for demographic information, past history, and course of treatment.
Investigators
Joseph Bubalo
PharmD
OHSU Knight Cancer Institute
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Average, median, and mode for substance P levels at different times
Secondary Outcomes
- Correlation of substance P levels with patient response (emesis or not)